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Abstract
Single oral dose therapy with fosfomycin trometamol (FT) 3 g is recommended in 
the treatment of uncomplicated urinary tract infection (UTI) not only in premeno-
pausal, but also in postmenopausal elderly, otherwise healthy women. It can also 
be used as reapplication every 10 days for prophylaxis of recurrent uncomplicated 
cystitis. FT 3 g has also been used with two oral doses of 3 g (on two consecutive 
days) for perioperative prophylaxis in transurethral interventions or with three doses 
(every other day, three times) for treatment of complicated lower UTI including 
many elderly patients. The tolerance and safety in the patients above 65 years 
of age did not differ from younger ones. Therefore, there is also an indication to 
administer oral FT 3g in adults above 65 years of age for treatment or prophylaxis 
of uncomplicated UTI.
Patients with renal insufficiency up to a creatinine clearance of 20 ml/min can be 
expected to have still sufficiently high urinary concentrations of fosfomycin, that 
treatment of cystitis should be justified from pharmacokinetic/pharmacodynamic 
point of view. From preliminary clinical results there is also an indication to use 
oral FT 3 g in adults with renal insufficiency up to a creatinine clearance of 20 ml/
min, with single dose for treatment of lower uncomplicated UTI with otherwise 
normal urinary tract or with repeated doses (every second or third day according 
to the degree of renal insufficiency) for treatment of lower complicated UTI caused 
by fosfomycin susceptible pathogens resistant to other oral antimicrobial drugs.
Introduction
In recent international and national guidelines the single oral 
therapy with fosfomycin trometamol (FT) is recommended as 
one of the first line empiric therapy of uncomplicated cystitis 
in women (1-3). Although this kind of short term therapy is 
well established in otherwise healthy premenopausal women 
(4-6), sometimes questions arise whether FT could also be 
used for the treatment of uncomplicated cystitis in elderly 
women, for prophylaxis of recurrent cystitis and prevention 
of postsurgical infections after urological interventions and 
probably with modified dosages also for the treatment of 
more complicated lower urinary tract infection (UTI) in male 
and female patients with and without reduced renal function.
The interest in the antibiotic therapy with FT was constantly 
raised, because there are only very few oral antimicrobials 
available which can be used empirically for the treatment 
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and prophylaxis of lower UTI in areas with a high incidence 
of ESBL-producing, fluoroquinolone and/or cotrimoxazole re-
sistant uropathogens (7-8). 
Aim of the review 
The aim of this review is to investigate whether the single 
dose therapy of FT is also justified in elderly patients with 
and without reduced renal function, its use for prophylaxis of 
recurrent cystitis and postsurgical infections after urological 
interventions and whether FT could also be used for more 
complicated lower UTI in male and female patients.
Three main questions have to be considered concerning us-
age of FT in renal insufficiency and in the elderly:
1.  What is the role of possible drug accumulation in patients 
with renal insufficiency after single dose therapy of 3 g FT 
in regard to adverse events?
2.  Are urinary concentrations in patients with renal insuf-
ficiency still sufficiently high enough that single dose 
therapy of 3 g FT is justified for treatment of acute un-
complicated urinary tract infections in women with renal 
insufficiency?
3.  What is the indication and clinical experience in patients 
with renal insufficiency with single dose therapy of 3 g FT?
4.  Is there a role of multiple oral doses of FT for the treat-
ment of male and female patients with more complicated 
cystitis due to fosfomycin susceptible uropathogens, which 
are resistant against other oral antimicrobial substances?
Methods
Literature search was performed in Medline and other sources 
concerning pharmacokinetics, pharmacodynamics and clini-
cal studies with FT in younger and older adult subjects with 
normal and impaired renal function. 
Results
Fosfomycin compounds
According to Della Bella & Ferrari (9) fosfomycin is a natural 
compound with a small molecular size (MW 138.06), pres-
ence of a carbon-phosphorus bond, and asymmetric carbon 
atom adjacent to an epoxide bridge. After stereo-specific 
binding to the target macromolecule, the oxygen bonds 
open into a reactive intermediate that irreversibly alkylates 
the nucleophilic active site of the bacterial membrane en-
zyme responsible for transforming N-acetyl-glucosamine into 
N-acetyl-muramic acid (Kahan et al. (10). The synthesis of the 
acetyl-muramyl pentapeptide “Park nucleotide” – the build-
ing block for the peptidoglycan polymer – is thus prevented. 
Fosfomycin, a strong phosphoric acid, is quite unstable. 
Therefore, it only can be administered in the form of some 
sort of salts. Fosfomycin sodium (FS) is used for parenteral 
administration. Fosfomycin calcium (FC) - used e.g. in Japan 
also for oral administration - is characterized by a fairly low 
water solubility and therefore poor bioavailability.
Of several diverse organic cations fosfomycin trometamol 
(FT) was proved preferable for oral therapy and is registered 
as “Monuril 3000” (Zambon/Pierre Fabre Pharma) corre-
sponding to 3.0 g fosfomycin and 2.631 g trometamol (total 
5.631g). FT is better water soluble, chemically stable at physi-
ological pH and has much better oral bioavailability than FC 
and thus higher serum and urinary concentrations after oral 
administration of the same dose (11). 
Pharmacokinetics of fosfomycin and trometamol 
in healthy subjects
After oral administration of 1.8 g of FT (equivalent to 1 g 
of acid fosfomycin) in 6 healthy subject two hours after oral 
administration the mean peak serum concentration of fos-
fomycin was 11.22 mg/l and that of trometamol 10.83 mg/l 
and 12 hours after oral administration 1.68 mg/l and 1.33 
mg/l, respectively. Thus, the serum concentrations and serum 
half lives of the two moieties, fosfomycin and trometamol, 
are very similar (Lodola and Longo, personal communication, 
1986, cited according to Della Bella & Ferrari (9). Since the 
two substances also have a similar molecular size (138.06 
and 121.14, respectively), the authors concluded that the two 
moieties may move across the intestinal barrier by the same 
kinetics. Whether this occurs in the form of the whole mol-
ecule or after dissociation is an open question. Unfortunately 
trometamol concentrations were only measured in healthy 
subjects and not in patients with renal impairment.
Absorption, pharmacokinetics and urinary 
antibacterial activity of FT as compared to FS  
and FC
Bergan (11) compared the absorption, pharmacokinetics and 
the urinary antibacterial activity of fosfomycin after i.v. ad-
ministration of fosfomycin sodium (FS) (50 mg/kg BW), af-
ter oral administration of FC (50 mg/kg BW), and after oral 
administration of FT (25 mg/kg and 50 mg/kg BW) in eight 
healthy volunteers (cross over study). In the following only 
the equivalent doses of 50 mg/kg BW of FS, FT and FC are 
discussed:
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1.  After i.v. bolus (5 min) administration of FS and oral admin-
istration of FT the peak serum concentrations are about 
10 times higher after i.v. (276 + 80 mg/l) as compared to 
that after oral administration (about 26 + 2.5mg/l) of FT. 
But about 4 hours after administration the serum con-
centrations after i.v. FS and after oral FT are already simi-
lar (about 18 mg/l, presented only in figure 1). The peak 
serum concentration after oral administration of FC was 
only 6.5 + 3.2 mg/l. 
2.  A mean serum half life was calculated for i.v. FS, oral FT 
and FC of 3.4 h, 3.6 h and 5.6 h, respectively. The longer 
apparent half life of FC as compared to FT is explained 
by the delayed absorption indicated by the delayed Tmax.
3.  The amount of drug absorbed from the oral doses is dis-
cernible from comparisons of the total areas under the 
serum concentration curves (AUC) compared to the same 
dose administered i.v. The mean bioavailability for FT was 
41 % and that of FC only 12 %.
4.  The mean urinary excretion up to 48 h after i.v. FS, oral FT 
and FC were 87 %, 43 % and 18 %, respectively.
5.  The mean urinary concentrations at 24 h, 36 h, and 48 h 
after administration were highest for oral FT (about 480, 
220, 110 mg/l, respectively), followed by oral FC (about 
260, 120, 100 mg/l, respectively) and lowest for i.v. FS 
(about 110, 25,<10 mg/l, respectively).
6.  The bacteriostatic titers were studied in urine samples tak-
en after 24, 36 and 48 h. The urine samples were diluted 
in nutrient broth to detect what dilution (titer) still had a 
concentration of fosfomycin that was sufficient to inhibit 
the growth of a selected strain each of Escherichia coli, 
Proteus mirabilis, Enterococcus faecalis and Pseudomonas 
aeruginosa. Unfortunately the author did not mention the 
MIC of the tested strains. It is also not clear, whether 
the same results would have been achieved, if the urine 
samples would have been diluted with urine instead of 
nutrient broth, because the inhibitory and bactericidal ac-
tivity depends also on the medium the study is performed. 
Nevertheless the results showed, that the urinary bacterio-
static titers at 24, 36 and 48 h for all strains were highest 
for oral FT, followed by oral FC and lowest for i.v. FS. For 
oral FT even after 48 h the bacteriostatic titer for E. coli 
was still about 1:256, for P. mirabilis 1:>64, for E. faecalis 
1:>8, and for P. aeruginosa 1:>64 demonstrating that the 
urinary concentrations up to 48 h after administration are 
still high enough to well inhibit growth of urinary patho-
gens (susceptible to fosfomycin).
Antibacterial activity of FT in an in vitro bladder 
model
Wiedemann & Gross (12) performed bacterial elimination 
studies. The urinary concentrations as obtained by volunteers 
were simulated in the in vitro model according to Grasso et 
al (1978-see in references). As nutrient broth in the mod-
el, N II Bouillon (Merck, Darmstadt) with an addition of 10 
mg/l glucose-6-phosphate was used. The following bacterial 
strains were tested: E. coli (MIC 1 mg/l), K. pneumoniae (MIC 
4 mg/l), E. cloacae (MIC 8 mg/l), S aureus (MIC 2 mg/l), S. 
faecalis (MIC 16 mg/l). According to the authors this implies 
that the concentration of the drug during a 1-day period is 
high enough to prevent the development of resistant mutants 
in all these strains.
A single oral dose of 0.5 g FT eliminated E. coli (MIC 1 mg/l) 
effectively without regrowth after 23 h. Other bacterial 
strains have been eliminated less effectively or showed re-
growth often with increased MIC. A 3-gram dose, however, 
was most effective and showed no regrowth of the strains 
tested after 23 h, although the effect on E. faecalis was still 
marginal. With this dosage no resistant mutants were ob-
tained from the test cultures.
Pharmacokinetics of FT in young and elderly 
adults.
Borsa et al. (13) performed a comparative pharmacokinetic 
study after oral administration of FT and FC in 5 young and 
healthy men (26-33 years) and in 8 elderly adults (65-82 years) 
at a dose of 25 mg/kg body weight (BW) (corresponding to 
fosfomycin). The young men had a mean (SD) endogenous 
creatinine clearance (Cl-Cr) of 127 + 20 ml/mim per 1.73 
m2 and the elderly adults that of 78 + 22 ml/min per 1,73 
m2. The maximal plasma concentration (Cmax) was reached 
on average in younger men/elderly adults at 1.61/2.16 hours 
after administration and amounted to 18.5/22.0 mg/l (dif-
ferences not statistically significant). The plasma half life was 
5.37 h and 8.28 h, respectively, and the apparent volume of 
apparent distribution was 2.42 l/kg and 1.47 l/kg, respective-
ly; both parameters also not statistically significant different. 
The urinary elimination of fosfomycin was on average in the 
younger 57.7% and in the elderly 27.5% (about half). The 
plasma clearance of fosfomycin was calculated on average 
as 324 ml/min per 1,73 m2 and 161 ml/min per 1,73 m2 and 
the renal clearance of fosfomycin as 180 ml/min per 1,73 m2 
and 49 ml/min per 1,73 m2.
From the study using an oral dose of 25 mg/kg1 BW of FT in 
younger and elderly it can be concluded:
•  T-max and C-max in younger and elderly are similar indicat-
ing about the same bioavailability in both groups 
•  the apparent volume of distribution of fosfomycin is about 
2 l/kg BW (2.4 in younger and 1.5 l/kg BW in elderly) which 
indicates a good tissue penetration. This is also shown in 
the study by Scaglione et al. (14) who found at 6 hours 
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and thereafter concentrations of fosfomycin in the bladder 
mucosa in the same range as in the serum.
•  the renal clearance of fosfomycin is higher than the corre-
sponding Cl-Cr indicating that fosfomycin is eliminated by 
the kidneys by glomerular filtration and tubular secretion
•  the terminal plasma clearance of fosfomycin is much higher 
than the renal clearance in both populations indicating that 
fosfomycin also has a considerable extra renal clearance 
(on average 196 ml/min per 1,73 m2 in the younger and 
112 ml/min per 1,73 m2 in the elderly without statistical 
significant difference)
•  since fosfomycin is mainly excreted by the kidneys, elderly 
adults with Cl-Cr moderately reduced to about 80 ml/min 
per 1,73 m2 show an increased plasma half life of about 
50% (increase from 5.4 h to 8.3 h).
Fosfomycin concentration after administration of 
FT in serum, urine and bladder mucosa in elderly 
patients.
Scaglione et al. (14) performed a pharmacokinetic study in 30 
patients (17 males, 13 females, mean age 60.4 + 4.7 years) 
with normal renal and hepatic function undergoing open sur-
gery because of bladder or prostate carcinoma. The patients 
received a single oral dose of 3 g FT. Serum, bladder mucosa 
tissue and urine concentrations were measured microbiologi-
cally until 24 h, 36 h, and 48 hours, respectively (table 1).The 
study shows that in patients with a mean age of about 60 
years of age the serum concentration is slightly higher than 
the maximal serum concentration of younger men (Borsa 
et al. (13) and in the range of that of elderly patients. The 
bladder mucosa tissue concentrations, which at 6 hours and 
thereafter were in the range of the serum concentrations 
demonstrating good tissue penetration as expected from the 
high apparent volume of distribution. 
Pharmacokinetics in patients with different 
grades of renal insufficiency and on hemodialysis 
as compared to healthy adults with normal renal 
function
Fillastre et al. (15) investigated the pharmacokinetics of FT in 
patients with different grades of renal insufficiency:
•  group I: 7 patients with Cl-Cr between 30 ml/min and 80 
ml/min.
•  group II: 6 patients with Cl-Cr between 10 ml/min and 
30 ml/min. 
•  group III: 5 patients with Cl-Cr between 2 ml/min and 10 
ml/min.
•  group IV: 5 patients on hemodialysis for 4 hours (Travenol 
CF.1511 with an surface of 1.20 m2).
•  and a control group: 5 male adults (26-33 years) with nor-
mal Cl-Cr (127 ml/min + 20 ml/min).
•  The control group was obviously the same 5 younger men 
as in the former study comparing younger and elderly 
adults (13) Borsa et al., 1988).
The subjects received after overnight fasting 25mg/kg2 FT 
and remained in fasting stage for further 3 hours. The mean 
results are shown in table 2.
The study shows that after oral administration of about 2 g 
of FT (25 mg/kg BW):
•  in healthy young men the mean Cmax (18.5 mg/l) is 
reached after 1.6 h and fosfomycin is excreted with a ter-
minal plasma half life of 5.4 h.
•  with increasing renal insufficiency (from group I to group 
III) the Tmax is delayed with up to 5.1 h in group III and 
Cmax is increased up to about twice the normal.
•  with increasing renal insufficiency (from group I to group 
III) the renal clearance of fosfomycin decreases according to 
the Cl-Cr and the urinary excretion within 24 h decreases 
accordingly. Unfortunately, urinary excretion was not mea-
sured longer than 24h (see Jangknecht et al. ( 16) with 
increasing renal insufficiency (from group I to group III) the 
terminal plasma half life increases to up to about 10 times 
in patients with severe renal insufficiency.
During hemodialysis Cmax was elevated as in patients with 
severe renal insufficiency and the plasma half life prolonged 
like in patients with severe renal insufficiency. It should, how-
ever, be noted that the pharmacokinetic during hemodialysis 
may depend very much on the type of dialysator used as well 
as on the dialysis regime (time, ultrafiltration).
Time
(h)
Serum
(mg/l)
Bladder 
Mucosa
(mg/kg)
Urine
(mg/l
3 24.5 + 4.3 13.0 + 5.1 2428 + 466
6 17.0 + 0.1 17.2 + 3.5 1906 + 172
12 6.7 + 1.7 7.3 + 2.1 1023 + 228
24 2.3 + 0.8 3.5 + 2.5 490 + 116
36 0.4 + 0.3 168 + 35
48 31 + 10
Table 1.  Fosfomycin concentrations in serum, bladder mu-
cosa and urine after oral administration of FT 3 g 
(according to Scaglione et al. 1994)
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Urinary concentrations elderly female patients 
with renal function impairment after oral 
administration of FT.
Jangknecht et al. (16) investigated the urinary concentrations 
in seven elderly female nursing-home patients aged 71 to 90 
years with renal function impairment indicated by an estimat-
ed Cl-Cr (Jeliffe Nr.4) between 21 and 72 ml/min. After oral 
administration of 3 g FT urine was collected in 12 h periods 
up to 84 h. The total urinary excretion of fosfomycin showed 
a fairly high range between 15 % and 60 % of administered 
dose: The higher the total urinary excretion the higher the 
urinary concentrations within in first 0-12h and 12-24 h and 
vice versa the lower the urinary concentrations 24-36 and 
36-48 h, respectively. 
In the three patients with the lowest Cl-Cr (21-28 mg/ml) 
the total urinary excretion were between 33 % and 57 % of 
administered dose. The urinary concentrations of these three 
patients were in the 12-24 h period between 328 and 1600 
mg/l and in the 36-48 h period between 122-365 mg/l.
From the results of this study it can be concluded that also 
in patients with severe renal insufficiency (Cl-Cr 20-30 ml/
min) the urinary concentrations after oral FT of 3 g are still 
sufficiently high and far above the MIC for susceptible patho-
gens with a breakpoint of <64 mg/l according to CLSI ( 17) or 
<32 mg/l according to EUCAST ( 18). In a European/Brazilian 
study with 2315 strains of E. coli collected from women with 
uncomplicated cystitis up to a breakpoint of <32 mg/l 96.5 
% of the E. coli strains were included ( 19). For the 243 E. 
coli strains from Germany the corresponding percentage was 
95.1 %. The MIC-90% for E. coli was 8 mg/l for the total 
study and 16 mg/l for Germany.
Clinical experience with single dose therapy of FT 
in women with acute uncomplicated UTI.
A metanalysis of 15 comparative studies and two additional 
large comparative studies published later showed an equiva-
lent clinical and bacteriologic efficacy and tolerance between 
3 g as single dose and comparative drugs (4-6). Therefore, FT 
can be recommended as a drug of choice in countries where 
it is available for the empiric therapy of uncomplicated cystitis 
in women (21). 
Clinical experience with single dose therapy of FT 
in elderly patients with UTI
Rudenko & Dorofeyev (here the paper of Rudenko & Dorofeyev 
should be cited) Rudenko N, Dorofeyev A, 2006. Treatment 
of acute non complicated cystitis in elderly women. Giornale 
Italiano di Microbiologia Medica Odontoiatrica e Clinica 10:3-
10. Treated 140 otherwise healthy postmenopausal women 
(mean (SD) age 70.6 (2.95) years) with symptoms of acute un-
complicated cystitis such as frequency, dysuria, urgency ( su-
prapubic pain was also present in 20 % of the patients) with a 
single oral dose of 3 g FT. The bacterial spectrum consisted of: 
E.coli (in 72,14% of the patients), E. faecalis (10,70%), S. sap-
rophyticus (4.29%), E. cloacae (2.86%), P.mirabilis (2.86%), 
K. pneumoniae (2.86%) , other pathogens (4.29%). 90% of 
the E. coli strains were susceptible to fosfomycin.
Control
Patients with renal insufficiency
p
Group I Group II Group III Group IV
Cl-Cr (ml/min) 127 + 20 30 - 80 10 - 30 2 - 10 hemodialysis
Dose (mg) 2032 1792 1667 1811 1836 >0.1 NS
Cmax (mg/l) 18.5 26.0 35.7 27.4 37.9 0.02 S
Tmax (h) 1.61 2.38 4.58 5.06 7.92 <0.001 S
AUC (mg x h/l) 103 389 1267 2109 2367 <0.001 S
T1/2 elim (h) 5.37 10.8 24.5 50.3 39.6 <0.001 S
Urine 24h % 58 32 24 11 - 0.004 S
CR-F (ml/min) 180 43 10 5.4 - <0.001 S
Table 2.  Pharmacokinetic parameters of fosfomycin in patients with various degrees of renal insufficiency after oral admin-
istration of FT (25mg/kg BW1) – according to Fillastre et al. 1988.
Cl-Cr – endogenous creatinine clearance; Cmax – maximal serum concentration; Tmax – time, when maximal serum concentration is reached; AUC – area 
under the time serum concentration; T1/2 – terminal half life; Urine 24h % - urinary excretion within 24 h as % of administered dose; CR-F – renal clear-
ance of fosfomycin.
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At the control visit, performed 7 days after the drug admin-
istration, 113 out of 126 (90%) patients were free of symp-
toms, in 8 (6%) there was an improvement, and in 5 (4%) the 
clinical pattern was unchanged. A bacterial cure was achieved 
in 110 out of 126 patients (87.3%); E. coli was eradicated in 
90 out of 91 (99%) patients. 
In the total population admitted to the study (n=140 pa-
tients), 15 adverse events were reported, however only 2 (al-
lergic reactions of moderate severity) were judged possibly 
related to the treatment.
MacGowan et al. (23) treated 20 hospitalized patients (me-
dian (range) age: 72 (47-88) years; only 6 patients were <65 
years) with UTI. A satisfactory bacteriological outcome was 
recorded in 11/17 of patients with susceptible pathogens and 
a satisfactory clinical outcome in 12/16 symptomatic patients. 
Three patients complained of possible adverse reactions: two 
had loose bowel motions 3 and 13 days after treatment, 
and one became drowsy, uncooperative and incontinent 60 
min. after therapy. In this patient, tolerance was classified as 
poor, but the relationship of these reactions to fosfomycin 
is uncertain.
Clinical experience with single dose therapy of FT 
in pregnancy
Bayrak et al. (24) treated 84 pregnant women in the second 
trimester of pregnancy with asymptomatic bacteriuria with 
single dose of 3 g FT as compared to cefuroxime axetile 250 
mg bid for 5 days. The microbiological elimination 7 days 
after therapy was 93.2 % with FT and 95 % with cefurox-
ime axetile. Both treatments were tolerated well. Only with 
cefuroxime axetile 2 cases (5 %) with vulvovaginitis were 
observed.
In three controlled studies a total of 250 pregnant women 
with asymptomatic bacteriuria were treated with a single oral 
dose of 3 g FT. The comparative substances were pipemidic 
acid 800 mg per day for 7 days in 156 patients, nitrofurantoin 
200 mg per day for seven days in 10 patients and amoxicillin 
3 g single dose in 31 patients (25). 
In study 1, the microbiological elimination rate 25-30 days 
after therapy with FT and pipemidic acid was 94% for both 
treatments. The rate was 77% and 68% for FT and amoxi-
cillin at four weeks in study 2. 15 days after therapy, the 
eradication rate was 84% and 90% with FT and nitrofuran-
toin (study 3). FT showed comparable results as with longer 
treatment using nitrofurantoin or pipemidic acid and showed 
better results than single dose therapy with amoxicillin. FT did 
not show any adverse events during pregnancy. The results 
also suggested that FT is safe in pregnancy from the point 
of view of foetal toxicity. Since treatment for asymptomatic 
bacteriuria is likely to be given only after the first trimester, 
thus it should be unlikely to have any influence on major 
malformations and chromosomal abnormalities (25). 
Clinical experience with two doses of FT for 
perioperative prophylaxis in transurethral 
interventions.
Periti et al. (26) used a double oral dose of 3 g FT for the 
perioperative prophylaxis in patients undergoing transurethral 
surgery: 3 g were administered 3 h before and 3 g 24 h after 
the intervention. The FT regimen was compared with two 
other regimens: amoxicillin 2 x 3 g, and cotrimoxazole 2 x 
1.92 g. A total of 675 patients undergoing TURP with a mean 
(SD) age of 63.3 (14) years were evaluated from 24 Italian cen-
tres. All three groups of patients were comparable concerning 
demography and intervention conditions. The patients had 
a postoperative indwelling urinary catheter on average for 
3-5 days. The results (table 3) showed a significantly better 
outcome with two doses of 3 g FT about one day apart in re-
gard to bacteriuria and symptomatic infections as compared 
to two doses of amoxicillin 3 g and cotrimoxazole 1.92 g.
Baert et al (27) performed a double-blind study in 61 pa-
tients undergoing TURP. 31 patients (mean (SEM) age: 69 
(1.45)) received 3g FT orally on the evening before and after 
the operation and 30 patients (mean (SEM) age: 66.1 (1.37)) 
received placebo. After removal of the transurethral catheter 
on the 5th day 0/31 in the FT group and 6/30 of the placebo 
group acquired UTI. There were no side effects registered.
Table 3.  Infectious complications and adverse events in 
patients with perioperative prophylaxis with two 
doses of fosfomycin tometamol (FT) 3 g and com-
pared with two doses of amoxicillin (AMX) 3 g and 
cotrimoxazole (CTX) 1.92 g.
AMX CTX FT
Patients (n) 207 212 256
Fever >38oC on 1st 
postop. day 5.3 % 4.2 % 1.5 %
Fever >38oC on 6th – 8th 
postop. day 4.3 % 4.2 % 0.4 %
Bacteriuria >105 CFU/ml 24.6 % 25.0 % 14.8 %*
Symptomatic infection 8.6 % 8.4 % 1.9 %*
Adverse events 8.2 % 7.5 % 4.7 %
* significantly (p<0.01) lower than with AMX and CTX.
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Di Silverio et al ( 28) included a total of 712 patients (521 
men and 191 women >14 years of age) undergoing trans-
urethral diagnostic and/or therapeutic manoeuvres. The oral 
dosage for perioperative prophylaxis was 3 g FT 3 h before 
and 3 g FT 24 h after the intervention. Out of 618 patients 
with sterile urine or with bacteriuria <105 CFU/ml on baseline 
screening, 20 (3.2 %) developed UTI on the 2nd day and 22 
(3.6 %) on the 7th day after treatment. Overall, a total of 
24 side effects were observed (3.3 %): nausea/vomiting 7, 
pyrosis 5, diarrhoea 5, constipation 1, skin rash 3, headache 
3. 16 (2.2 %) of which were considered by the authors FT 
treatment associated.
Clinical experience with multiple doses of FT 3 g 
in patients with complicated cystitis
Pulluku et al. (29) treated 52 patients (aged 55.0 + 18.3, 
rage 19-85; 25 males, 27 females) with clinical symptoms of 
cystitis with dysuria, frequency or urgency, with pyuria with 
>20WBC/mm3 in urine and an ESBL-producing E. coli (>105 
CFU/ml); no leukocytosis or fever; 36 of them had complicat-
ing factors such as indwelling catheter-7, hemi- or quadri-
paresis -2, malignancy of the urinary tract – 4, other malig-
nancies – 4, diabetes mellitus - 5, nephrolithiasis – 3, recent 
urological interventions – 6, and were diagnosed complicated 
cystitis. All patients received FT ( 3 g every other night, three 
times). Overall clinical and microbiological success was 94.3 
% (49/52) and t8.5 % (41/52), respectively, at 7 to 9 days 
after therapy. Relapse and reinfection rates were 0 % (0/28) 
and 10.7 % (3/28), respectively. None of the patients stated 
any side effect. 
Senol et al (30) treated in an observational prospective com-
parative study 47 patients with complicated lower UTI caused 
by ESBL-producing E. coli. 27 patients (13 males, 14 females, 
aged 57.5 + 15.3 years), of whom 19 had complicating fac-
tors, were treated orally with FT 3 g every other night three 
times. 20 patients (7 males, 13 females, aged 57.5 + 20.7 
years) were treted with meropenem (1 g tid i.v.) or imipenem 
(500 mg four times daily) for 14 days. Clinical and microbio-
logical success in the FT and carbapenem groups was simi-
lar (21/27 vs 19/20 and 16/27 vs. 16/20, p>0.05). Although 
it was not a randomised controlled study, according to the 
authors the data show that FT may be a suitable, effective 
and cheap alternative in the treatment of ESBL-producing E. 
coli-related complicated lower UTI.
Shrestha et al (31) treated a 85 year old man with complicated 
UTI due to a vancomycin-resistant Enterococcus spp. with FT 
3 g orally every 3 days for 3 weeks. In the history the pa-
tient had a renal insufficiency (CL-Cr 25 ml/min), obstructive 
urogenital symdrome with BPH, several times transurethral 
catheterisations, TURP, epididymo-orchitis and recurrent chills 
and shiverings. After the 2nd dose of FT the symptoms disap-
peared. The patient had no clinical recurrence until 2 years 
after therapy.
Clinical experience with multiple doses of FT 3 g 
in patients with recurrent UTI
Rudenko & Dorofeyev (22) Rudenko N, Dorofeyev A, 2005. 
Prevention of urinary tract infections by long-term administra-
tion of fosfomycin trometamol. Arzneim.-Forsch,/Drug Res. 
55:420-7. Performed a double-blind, randomised prospec-
tive placebo-controlled study in 317 women with recurrent 
cystitis. The patients received every 10 days FT 3 g orally or 
placebo for 6 months. The follow-up was until 12 months. 
302 patients stayed throughout the study which represents 
a good compliance. The number of UTI per patient year was 
0.14 in the FT group and 2.97 in the placebo group, which 
was statistically significant different (p<0.001). FT was toler-
ated well.
Ruxer et al. (32) included 50 women with recurrent UTI and 
type 2 diabetes mellitus into their study. 25 patients (aged 
57.8 + 7.6 years) received every 30 days FT 3 g orally and 25 
patients (aged 60.0 + 7.9) received notrofurantoin retard 100 
mg bid for 7 days and thereafter 100 mg qd for 6 months. 
There was no significant difference between the study group 
in whom no UTI was seen at 3 and 6 month of long-term 
treatment. No clinically relevant adverse reaction or signifi-
cant laboratory abnormality were observed in the FT group. 
In the nitrofurantoin group only one patient reported vertigo 
of several days that was most likely related to the study drug.
Discussion 
According to the recently published German guidelines on 
management of uncomplicated UTI (3), uncomplicated cysti-
tis can be observed in the following patients’ groups:
• otherwise healthy non pregnant premenopausal women.
• otherwise healthy pregnant women.
• otherwise healthy postmenopausal women.
• otherwise healthy younger men.
•  otherwise healthy patients with diabetes mellitus and sta-
ble metabolism.
Fünfstück et al (34) reported that a lower UTI (cystitis) in 
patients with mild and moderate renal insufficiency (without 
oliguria) and with normal urinary tract can also be classified 
as uncomplicated, because such an infection has no adverse 
impact on renal function.
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The single oral dose therapy with FT 3 g is established in 
acute uncomplicated cystitis in women. This was mainly in-
vestigated in a variety of studies with several comparators in 
premenopausal otherwise healthy women ( 4,5,6,18). In the 
meantime, clinical studies also have shown that the single 
dose therapy with FT 3 g can also be used in otherwise 
healthy pregnant women (24-25) and in otherwise healthy 
postmenopausal women (22) . Many of these women were 
older than 65 of years. In addition, MacGowan et al. (23) 
treated 14 hospitalised patients aged above 65 years with 
mainly complicated UTI also with the single dose therapy with 
FT 3 g with satisfactory results. For perioperative prophylaxis 
for transurethral interventions two doses of FT 3 g one day 
apart were used ( 26-28). In these 3 studies a total of 905 
patients treated with two doses of FT 3 g were analysed; 
many of them, especially in the two studies on perioperative 
prophylaxis in TURP were males and above the age of 65 
years( 26-27). Further more, in these two studies and the 
one case report, in which FT 3g was administered every other 
or third (one case) day three times or in the case report for 
3 weeks, most of the patients were above 65 years of age. 
All these clinical studies found no evidence that the toler-
ance and safety of single dose or multiple doses of oral FT 
3 g were different compared to single dose of oral FT 3g in 
premenopausal younger women. Therefore, based on clinical 
safety and tolerance there is no reason to restrict the use of 
oral FT 3 g therapy to the age until 65 years.
It can also be expected that some of the patients above 65 
years of age had already at least a moderate renal insuf-
ficiency. Therefore, it is important to consider the use of FT 
also from this point of view.
The pharmacokinetic studies show that at least above a renal 
insufficiency with an endogenous creatinine clearance of 20 
ml/min the urinary concentrations on the first and second day 
after oral administration of FT 3 g are still sufficiently high 
and above the MICs of susceptible uropathogens. Therefore, 
the urinary antibacterial activity should also be sufficient to 
eliminate susceptible uropathogens. Although there are no 
data on urinary concentrations in patients with a Cl-Cr lower 
than 20 ml/min, it sill can be postulated that in patients with 
any amount of urine production the urinary concentration of 
fosfomycin will be at least as high as the plasma concentra-
tion because FT is practically not protein bound and filtered 
by the glomeruli. Therefore, the urinary concentrations may 
also be effective to some extent in such situations considering 
a MIC-90% of 8-16 mg/l for E. coli, as found in the ARESC 
study (19).
Since fosfomycin is mainly excreted by the kidneys by glo-
merular filtration and tubular secretion, it can be expected 
that the plasma half life will be prolonged in patients with 
renal insufficiency. In patients with Cl-Cr between 10-30 ml/
min an 5 times increase and in patients with Cl-Cr between 
2-10 ml/min a 10 times increase of plasmy half life as com-
pared to subjects with normal renal function was observed 
on average (15). After a single dose of FT 3 g, however, 
the peak plasma concentration is only doubled in patients 
with Cl-Cr between 10-30 ml/min as compared to subjects 
with normal renal function. There is no reason to anticipate 
that the doubling of peak plasma concentration should cre-
ate any problems in regard to safety and tolerance, if these 
peak plasma concentrations are compared with peak plasma 
concentrations after i.v. administered of FS (same dose). After 
i.v. administration the peak plasma concentration is 10 times 
higher as compared to oral administration in subjects with 
normal renal function of the same dose (11). 
Therefore, Dose modification according to the grade of re-
nal insufficiency should be performed beginning from GFR 
< 60 ml/min (Hartmann et al. (35). In general, this can be 
done either by reducing the dose (Dettli 1, cited according to 
Hartmann et al. (35) or by prolongation of the dosing interval 
(Dettli 2, cited according to Hartmann et al. (35). If it is nec-
essary to obtain less fluctuation of the peak concentration, 
the modification according to Kunin (cited according to Hart-
mann et al. (35) should be used; after the first normal dose 
every half life half of the initial dose is repeated. However, 
what ever dosing modification is used for antibiotic therapy 
always the first dose should be the normal dose as in patients 
with normal renal function. Therefore, a dose reduction of a 
single dose therapy even in patients with severe renal impair-
ment is obsolete in any case.
For repeated dosing the prolongation of half life has to be 
considered. Almost no accumulation of the drug will occur if 
the drug is administered every 3 half lives. Since in younger 
patients with normal renal function the plasma half life is 
about 5 h, a once daily administration should not cause any 
drug accumulation. To use two doses (one day apart) as for 
perioperative prophylaxis should not cause any drug accumu-
lation in patients with a creatinine clearance above 80 ml/min 
and cause only slight accumulation in patients with creati-
nine clearance of 30-80 ml/min. In patients with renal insuf-
ficiency with creatinine clearance between 10-30 ml/min, the 
second dose should either be administered every second or 
third day or the daily dose should be reduced after the first 
regular dose to 1/3 of the normal dose at the following days.
Since FT is mainly used for the treatment of lower UTI, be-
cause the plasma concentrations after 3 g single dose are not 
high enough in younger patients with normal renal function 
for treatment of systemic infections, the limiting factor in re-
nal insufficiency might be the urinary concentrations reached. 
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Unfortunately no data on urinary concentrations are available 
below a creatinine clearance of 20 ml/min. But for this degree 
of renal insufficiency the urinary concentrations seem to be 
sufficiently high that at least from pharmacokinetic/pharma-
codynamic point of view a single dose of FT 3 g could be 
used for the treatment of lower UTI also in these patients 
if there are no abnormalities within the urinary tract. For 
complicated cystitis repeated doses of FT have shown already 
good results in preliminary studies. In elderly patients in pa-
tients with reduced renal function the repeated dose should 
be given every second or in patients with more severe renal 
impairment every third day.
In patients with normal renal function it was shown that 
fosfomycin and trometamol are absorbed and eliminated in 
the same range (Lodola and Longo, personal communication, 
1986, cited according to Della Bella & Ferrari(9). For patients 
with renal insufficiency the pharmacokinetic data concern-
ing global body clearance and urinary excretion are also very 
similar (15, 33). Therefore all considerations regarding fosfo-
mycin can be translated cum grano salis also to trometamol 
assuming that the degree of renal function has no major 
influence an the gastrointestinal absorption of trometamol. 
Trometamol has been used as organic base as a buffer for 
metabolic acidosis also in patients with severe renal insuf-
ficiency and even in anuric patients. Since a single 3 g oral 
dose of FT corresponds to less than 1/4-1/5 of the lowest dose 
of i.v. dose of trometamol in patients with renal insufficiency 
to correct metabolic acidosis, no additional side effects in pa-
tients with renal insufficiency may have to be expected from 
the trometamol moiety except if there is a hypersensitivity 
to trometamol. Even a 4 to 5 times repeated 3g dose of FT 
would only amount to the lowest recommended i.v. dose in 
patients with renal insufficiency to correct metabolic acidosis.
Conclusion
Single oral dose therapy with FT 3 g is recommended for 
treatment and prophylaxis of uncomplicated UTI not only in 
premenopausal, but also in postmenopausal elderly, other-
wise healthy women above 65 years of age, because toler-
ance and safety of FT did not differ from younger ones. FT 
3 g has also been used with two oral doses of 3 g (on two 
consecutive days) for perioperative prophylaxis in transure-
thral interventions or with three doses (every other day, three 
times) for treatment of complicated lower UTI including many 
elderly patients. Up to a creatinine clearance of 20 ml/min 
urinary concentrations of fosfomycin can still be expected 
to be sufficiently high for single dose therapy of UTI caused 
by fosfomycin susceptible uropathogens even in cystitis of 
elderly patients with otherwise normal urinary tract.
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